Sweden's Nanologica Q1 net sales more than double on Syntagon acquisition

Nanologica AB (publ)

20/05/2026 07:17

Overview

Sweden life science group's Q1 net sales more than doubled, driven by Syntagon acquisition

Operating profit turned positive, impacted by Syntagon acquisition recorded as operating income

Company completed share issues and rights issue, strengthening cash position and balance sheet

Outlook

Company expects Syntagon acquisition to contribute positively to earnings and cash flow from 2026

Nanologica plans to devote more resources to sales and marketing to accelerate growth

Company sees stable silica production and increased market activity as supporting future development

Result Drivers

SYNTAGON ACQUISITION - Syntagon contributed SEK 18.8 mln to Q1 net sales and was recorded as operating income, driving operating profit positive

SILICA PRODUCTION - Stabilized large-scale silica production enabled delivery to larger customers and improved yields

COMMERCIAL ACTIVITY - Increased market activity and new orders from pharmaceutical customers supported sales

Company press release: ID:nMFN5l0MwB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 21.46 mln
Q1 Adjusted EPS
SEK 0.72


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)